BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 384 filers reported holding BIO-TECHNE CORP in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $3,701,751 | +10.7% | 47,975 | -2.4% | 0.85% | +2.8% |
| Q3 2023 | $3,344,619 | -16.6% | 49,135 | 0.0% | 0.82% | -13.0% |
| Q2 2023 | $4,010,890 | +7.8% | 49,135 | -2.0% | 0.95% | +4.9% |
| Q1 2023 | $3,720,257 | -10.6% | 50,145 | -0.5% | 0.90% | -12.2% |
| Q4 2022 | $4,161,162 | -99.9% | 50,420 | +285.8% | 1.03% | +3.0% |
| Q3 2022 | $3,711,880,000 | -18.1% | 13,070 | 0.0% | 1.00% | -13.8% |
| Q2 2022 | $4,530,584,000 | -20.0% | 13,070 | 0.0% | 1.16% | -11.7% |
| Q1 2022 | $5,659,832,000 | -21.4% | 13,070 | -6.1% | 1.31% | -18.4% |
| Q4 2021 | $7,198,268,000 | +66.2% | 13,914 | -15.2% | 1.61% | +9.7% |
| Q3 2021 | $4,331,276,000 | -33.2% | 16,402 | +13.9% | 1.47% | -7.9% |
| Q2 2021 | $6,482,393,000 | +17.1% | 14,397 | -0.7% | 1.59% | +10.2% |
| Q1 2021 | $5,536,839,000 | +10.8% | 14,497 | -7.9% | 1.45% | +1.6% |
| Q4 2020 | $4,995,696,000 | +59.7% | 15,732 | -4.7% | 1.42% | +13.6% |
| Q3 2020 | $3,129,109,000 | -27.8% | 16,502 | +0.6% | 1.25% | -14.6% |
| Q2 2020 | $4,331,276,000 | +38.4% | 16,402 | -0.6% | 1.47% | +17.1% |
| Q1 2020 | $3,129,109,000 | -17.1% | 16,502 | -4.1% | 1.25% | +6.8% |
| Q4 2019 | $3,776,011,000 | +13.3% | 17,202 | +2.4% | 1.17% | +3.9% |
| Q3 2019 | $3,332,676,000 | -5.4% | 16,802 | -0.3% | 1.13% | -7.5% |
| Q2 2019 | $3,521,730,000 | +3.8% | 16,852 | -1.4% | 1.22% | +0.6% |
| Q1 2019 | $3,393,616,000 | +36.9% | 17,092 | -0.2% | 1.22% | +21.0% |
| Q4 2018 | $2,478,330,000 | -28.4% | 17,125 | +0.9% | 1.00% | -19.9% |
| Q3 2018 | $3,463,746,000 | +33.3% | 16,970 | -3.6% | 1.25% | +23.8% |
| Q2 2018 | $2,599,109,000 | -2.9% | 17,595 | -0.8% | 1.01% | -4.6% |
| Q1 2018 | $2,677,365,000 | +2.8% | 17,745 | -11.1% | 1.06% | +4.0% |
| Q4 2017 | $2,604,616,000 | -0.6% | 19,970 | -4.0% | 1.02% | -6.2% |
| Q3 2017 | $2,619,746,000 | +1.4% | 20,806 | -5.0% | 1.09% | -0.5% |
| Q2 2017 | $2,584,547,000 | +13.4% | 21,900 | -2.2% | 1.09% | +8.9% |
| Q1 2017 | $2,278,976,000 | -2.2% | 22,400 | -0.6% | 1.00% | -4.6% |
| Q4 2016 | $2,329,553,000 | -7.1% | 22,525 | -1.6% | 1.05% | -9.2% |
| Q3 2016 | $2,506,455,000 | -3.6% | 22,890 | -0.1% | 1.16% | -3.0% |
| Q2 2016 | $2,600,285,000 | +16.1% | 22,910 | -3.3% | 1.20% | +13.0% |
| Q1 2016 | $2,239,000,000 | +10.0% | 23,690 | +1.4% | 1.06% | +2.5% |
| Q4 2015 | $2,035,000,000 | -8.7% | 23,370 | -3.1% | 1.03% | -12.5% |
| Q3 2015 | $2,230,000,000 | -5.9% | 24,130 | +0.3% | 1.18% | +0.2% |
| Q2 2015 | $2,369,000,000 | +3.1% | 24,060 | +3.6% | 1.18% | +3.2% |
| Q1 2015 | $2,297,000,000 | +36.8% | 23,230 | +27.8% | 1.14% | +40.2% |
| Q4 2014 | $1,679,000,000 | – | 18,175 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |